(-)-Epicatechin dosing in normal and overweight / obese subjects showed a 30% reduction in C-reactive protein, a key marker of inflammation in the body
Published November 2016
This randomized, placebo-controlled, and double-blind study was conducted on 30 normal and overweight/obese adult volunteers for 4 weeks. A precise purity and precise dosage of (-)-epicatechin (key ingredient in Mitokatylst™ – E) was administered to the treated group. Metabolic responses of all the subjects were examined using indirect calorimetry and determining blood glucose and triglycerides at 0, 2 and 4 hours after metabolic load ingestion.
Key Takeaways
- A significant result was the reduction of the levels of high-sensitivity C-reactive protein (hs-CRP) by 30.2% in the treated group; the placebo group did not show any change in their hsCRP levels. The hsCRP test is used to estimate inflammation in the body and can help predict the risk of heart disease and stroke.
- Test results for the treated subjects showed significant decreases in triglycerides (30%) versus the placebo group (12.9%). The group receiving (-)-epicatechin also showed a 25.8% reduction in their TG/HDLc index whereas the placebo group showed a 5.7% reduction.
- The effects of (-)-epicatechin were more prominent in the overweight subjects.
Authors
Gabriela Gutiérrez-Salmeán, Eduardo Meaney, Miguel A. Lanaspa, Christina Cicerchi, Richard J. Johnson, Sundeep Dugar, Pam Taub, Israel Ramírez-Sánchez, Francisco Villarreal, George Schreiner, Guillermo Ceballos